Bioventix PLC (BVXP)

Industry Biotechnology


This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

1,650.00p

Buy

1,750.00p

arrow-down-25.00p (-1.45%)

Prices updated at 12 Dec 2025, 16:23 GMT
| Prices minimum 15 mins delay
|
Prices in GBX

Bioventix PLC is engaged in the field of biotechnology. Its business involves the development of high-affinity sheep monoclonal antibodies and clinical diagnostics and drugs of abuse testing.

Income statement

20242025
14m13m
13m12m
11m10m
78.1076.80
8m8m
11m10m
Sales, General and administrative2m2m
Interest expenses--
Provision for income taxes3m3m
Operating expenses2m2m
Income before taxes11m10m
Net income available to common shareholders8m8m
1.5031.4527
Net interest income201,962192,349
Advertising and promotion--
Net investment income, net-42,180-170,006
Realised capital gains (losses), net--
Total benefits, claims and expenses--
Earnings per share (diluted)1.48121.4329
Free cash flow per share1.57231.3249
Book value/share2.29952.2109
Debt equity ratio--

Balance sheet

20242025
Current assets13m12m
Current liabilities2m1m
Total capital12m12m
Total debt--
Total equity12m12m
Total non current liabilities--
Loans--
Total assets14m13m
Total liabilities--
Cash and cash equivalents6m5m
Common stock5m5m

Cash flow

20242025
Cash at beginning of period6m6m
Cash dividends paid-8m-8m
8m7m
Investments (gains) losses186,055173,160
6m5m
Net income--
8m7m
-15,907-19,189
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.